Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis

Details for Australian Patent Application No. 2004231078 (hide)

International Classifications

Event Publications

17 November 2005 PCT application entered the National Phase

PCT publication WO2004/092219 Priority application(s): WO2004/092219

24 August 2006 Change of Name(s) of Applicant(s), Section 104

Protien Design Labs, Inc. The name of the applicant has been changed to PDL BioPharma, Inc.

22 October 2009 Assignment before Grant

PDL BioPharma, Inc. The application has been assigned to Facet Biotech Corporation

3 February 2011 Alteration of Name

The name of the applicant has been altered to Abbott Biotherapeutics Corp.

9 June 2011 Application Accepted

Published as AU-B-2004231078

6 October 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.